世卫组织建议使用GLP-1药物治疗肥胖症,强调组合治疗和公平获得治疗。 WHO recommends GLP-1 drugs for obesity, stressing combo treatment and equitable access.

世界卫生组织发布了首个全球指南，推荐使用GLP-1受体激动剂，如司美格鲁肽和替泽帕肽，用于长期肥胖治疗，承认其为影响超过十亿人的慢性疾病。 The World Health Organization has issued its first global guidelines recommending GLP-1 receptor agonists, like semaglutide and tirzepatide, for long-term obesity treatment, recognizing it as a chronic disease affecting over a billion people. 该指南强调将药物与生活方式支持和健康环境相结合,同时指出高成本、获取机会有限和假冒风险等挑战。 The guidance stresses combining medication with lifestyle support and healthy environments, while noting challenges such as high costs, limited access, and counterfeit risks. 世卫组织呼吁公平分配、扩大生产和加强卫生系统,以应对肥胖症对健康和经济的不断上升的全球影响。 WHO calls for equitable distribution, expanded production, and stronger health systems to tackle obesity’s rising health and economic impact worldwide.